Adv Pediatr 33:95126 Gretz N, Manz F, Augustin R, Barrat TM, Bender-Gotze C, Brandis M, Bremer HJ, Brodehl J, Broyer M, Bulla M, Callis L, Chantler C, Diekmann L, Dillon MJ, Egli F, Ehrich JH, Endres W, Fanconi A, Feldhoff C, Geisert J, Gekle D, Gescholl-Bauer B, Grote K, Gruttner R, Hagge W, Haycock CB, Hennemann H, Klare B, Leupold D, Lohr H, Michalk D, Oliveira A, Ott F, Pistor K, Rau J, Scharer K, Schindera F, Schmidt H, Schulte-Wissermann H, Verrier-Jones K, Weber HP, Willenbockel U, Wolf H (1983) Survival time in cystinosis
Revision requested March 10, 2022
This is exactly why the review process exists: to help ensure that decisions are based on evidence, viability, and clinical need, rather than demand or trend
CagriSema may follow similar patterns, eventually becoming accessible through standard medical channels for men who meet criteria